Redwood Bioscience
acquired by Catalent Pharma SolutionsEmeryville, US · 2 known investors
Developed site-specific protein conjugation and linker technologies; acquired by Catalent Pharma Solutions in 2014.
Founders & leadership
DR
DAVID RABUKAFounder
MB
MICHAEL BLANKExecutive
KM
KAREN M BOEZIExecutive
Board
JG
J GORDON FOULKESBoard director
EM
EDWARD MCCRACKENBoard director
BL
BARRY LITTLEJOHNSBoard director
Investors · 2
Reported raises · per SEC filings
Form D private placements$2.5M disclosed across 1 round · 2014
▶$2.5MraisedJan 2014 · 1 investors · BiotechnologyRule 506(b)
▶$2.5MraisedJan 2014 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- EDWARD MCCRACKENDirector
- BARRY LITTLEJOHNSDirector
- MICHAEL BLANKExecutive Officer
- J GORDON FOULKESDirector
- DAVID RABUKAExecutive Officer, Director
- KAREN M BOEZIExecutive Officer, Director
- Offering amount
- $2.5M
- Amount sold
- $2.5M
- First sale
- Jan 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Redwood Bioscience do?
- Developed site-specific protein conjugation and linker technologies; acquired by Catalent Pharma Solutions in 2014.
- Who founded Redwood Bioscience?
- Redwood Bioscience was founded by DAVID RABUKA.
- Who are Redwood Bioscience's investors?
- Redwood Bioscience's investors include Mission Biocapital, Takeda Ventures.
- How much funding has Redwood Bioscience raised?
- Redwood Bioscience has disclosed $2.5M raised across 1 round.
- Who acquired Redwood Bioscience?
- Redwood Bioscience was acquired by Catalent Pharma Solutions.
- Where is Redwood Bioscience headquartered?
- Redwood Bioscience is headquartered in Emeryville, US.